Is adjuvant olaparib standard of care in all high-risk HER2-negative early breast cancer presenting <i>gBRCA1/2</i> mutations?

ABSTRACT:

SUBMITTER: Foidart P 

PROVIDER: S-EPMC11921398 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature